The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 13, 2025

Filed:

Jan. 24, 2024
Applicant:

Ascendis Pharma Bone Diseases A/s, Hellerup, DK;

Inventors:

Kennett Sprogøe, Holte, DK;

Guillaume Maitro, Mannheim, DE;

Mathias Krusch, Hirschhorn, DE;

Thomas Wegge, Heidelberg, DE;

Joachim Zettler, Heidelberg, DE;

Lars Holten-Andersen, Vanløse, DK;

David Brian Karpf, Mountain View, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/29 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 47/54 (2017.01); A61K 47/60 (2017.01); A61K 47/34 (2017.01);
U.S. Cl.
CPC ...
A61K 38/29 (2013.01); A61K 9/0019 (2013.01); A61K 9/1647 (2013.01); A61K 47/54 (2017.08); A61K 47/545 (2017.08); A61K 47/60 (2017.08); A61K 47/34 (2013.01);
Abstract

The invention provides a method of treating or controlling hypoparathyroidism in a human patient by administering to the human patient a pharmaceutical composition comprising a controlled-release PTH compound or a pharmaceutically acceptable salt thereof. The controlled-release PTH compound comprises a PTH moiety reversibly conjugated to a branched polyethylene glycol carrier. The composition is administered by subcutaneous injection no more frequently than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered by subcutaneous injection at the same dosing frequency required to maintain a serum albumin-adjusted calcium level in serum of above 8.5 mg/dL over a 24 hour period.


Find Patent Forward Citations

Loading…